Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

v3.22.2.2
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Restricted Stock Unit Activity
A summary of our restricted stock unit activity under the 2018 Plan for the nine months ended September 30, 2022 is set forth below:
Shares Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2021 3,576,270  $ 1.94 
Granted 1,292,000  1.58 
Released (1,409,494) 1.76 
Forfeited (105,000) 2.22 
Outstanding as of September 30, 2022 3,353,776  $ 1.86 
Schedule of Stock Options
A summary of our stock option activity under the 2018 Plan and related information is as follows:
Number of Shares Weighted Average
Exercise Price
Weighted Average
Remaining
Contractual Term
(years)
Aggregate Intrinsic
Value
Outstanding as of December 31, 2021 50,000  $ 1.08  1.37 $ 78 
Granted 50,000  1.70 
Exercised —  — 
Forfeited (12,500) 1.08 
Outstanding as of September 30, 2022 87,500  $ 1.43  5.9 $
Exercisable as of September 30, 2022 68,750  $ 1.36  4.82 $
A summary of our stock option activity under the 2009 Plan and related information is as follows:
Number of Shares Weighted Average
Exercise Price
Weighted Average
Remaining
Contractual Term
(years)
Aggregate Intrinsic
Value
Outstanding as of December 31, 2021 925,467  $ 0.80  5.59 $ 1,692 
Granted —  — 
Exercised (22,757) 0.68 
Forfeited (5,481) 2.00 
Outstanding as of September 30, 2022 897,229  $ 0.80  4.96 $ 452 
Exercisable as of September 30, 2022 896,155  $ 0.80  4.96 $ 452 
Schedule of Condensed Income Statement
Compensation costs that have been included in our condensed consolidated statements of operations and comprehensive (loss) income for all stock-based compensation arrangements is set forth below:
Three Months Ended September 30, Nine Months Ended September 30,
Stock-based compensation 2022 2021 2022 2021
Cost of revenues $ 59  $ 352  $ 154  $ 884 
Sales and marketing 35  140  80  371 
General and administrative 760  790  1,827  2,124 
Research and development 45  213  108  554 
Total stock-based compensation $ 899  $ 1,495  $ 2,169  $ 3,933